Secondary translational analysis of a phase III trial in 555 patients with endocrine-resistant HR+/HER2- metastatic breast cancer: low baseline thymidine kinase activity was associated with longer PFS (11.4 vs 4.0 months) but did not predict benefit between arms.
RCTn = 555
Guerrero-Zotano et al. Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial